← Back to Clinical Trials
Recruiting NCT07365579

NCT07365579 Design and Feasibility of an SMS-based Safety Planning Intervention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07365579
Status Recruiting
Phase
Sponsor Northwestern University
Condition Suicidal Ideation and Behavior
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-06-02
Primary Completion 2027-05-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 24 Years
Study Type INTERVENTIONAL
Interventions
Text Messaging based Safety Planning InterventionFacilitated Referral to Crisis Resources

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-06-02 with a primary completion date of 2027-05-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is testing whether it is feasible to run a larger randomized controlled trial and whether an automated text messaging program is acceptable to young adults who have suicidal thoughts. The program is designed to help participants create and use a safety plan, which is a personalized list of warning signs, coping strategies, supportive people, professional resources, ways to make their environment safer, and reasons for living. After joining and completing an initial survey, participants are randomly assigned by a computer to one of two groups. One group starts right away with the interactive safety planning text program. The other group first receives simple text messages with 24/7 crisis resources and then, after four weeks, also receives the interactive safety planning program. Participants use the text program for about four weeks and complete online surveys at the start and again over a total period of 24 weeks.

Eligibility Criteria

Inclusion Criteria: 1. Ages 18 to 24 \*The age to provide consent in Nebraska is 19. Individuals recruited from the state of Nebraska must be 19 or older. 2. endorsement of past 2-week suicidal ideation 3. Resident of the United States 4. Owns a smartphone Exclusion Criteria: 1. Serious mental illness for which intervention would be contraindicated (i.e., active psychosis or mania) 2. Imminent suicidality (i.e., experiencing active suicidal ideation with a plan and intent to act) 3. Written English language skills that are insufficient to engage in the consent, design, evaluation, or intervention procedures.

Contact & Investigator

Central Contact

Jonah Meyerhoff, PhD

✉ jonah.meyerhoff@northwestern.edu

📞 312-503-1232

Principal Investigator

Jonah Meyerhoff, PhD

PRINCIPAL INVESTIGATOR

Northwestern University

Frequently Asked Questions

Who can join the NCT07365579 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 24 Years, studying Suicidal Ideation and Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07365579 currently recruiting?

Yes, NCT07365579 is actively recruiting participants. Contact the research team at jonah.meyerhoff@northwestern.edu for enrollment information.

Where is the NCT07365579 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT07365579 clinical trial?

NCT07365579 is sponsored by Northwestern University. The principal investigator is Jonah Meyerhoff, PhD at Northwestern University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology